Drugmaker Shire said on Tuesday it was seeking to buy Baxalta for $30 billion to forge the leading global specialist in rare diseases.» Read More
California may be dry, but water-breeding mosquitoes, and the diseases they carry, still may have another big year in 2015.
A 66-year-old man turned himself in after 39 years of running in order to receive health care benefits in prison, NBC News reports.
The creators behind a lifelike hologram of Michael Jackson now want to bring the first digital human to healthcare.
After its unsolicited takeover bid was denied, Mylan plans to make a new offer for Perrigo, according to a source familiar with the matter.
Roche, the world's biggest maker of cancer drugs, reported a 3 percent rise in sales in the first quarter on Wednesday.
As a corruption scandal involving South Korea's top politicians rages on, the manufacturer of a popular beverage has emerged as an unexpected beneficiary.
A study of 95,000 kids found absolutely no link between the measles vaccine and autism, even in children with autistic siblings.
Avian flu is proving economically painful, especially in Iowa and Wisconsin, but scientists say the danger may not extend to human health.
For the first time since late 2012, Obamacare may have slightly more fans than foes, a survey says.
Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10.
Here are how some food-related stocks are moving on news of an avian flu outbreak in Iowa.
Just 68,000 people have signed up for HealthCare.gov plans during a grace period for those subject to an fine.
A new round of funding could propel small, data-driven health insurer Oscar into a major playing field for Obamacare plans.
Changes in the prescription drug market may have curbed prescription opioid abuse but may have also fueled a rise in heroin use.
Sofia Vergara's ex wants to prevent two frozen embryos they conceived from being destroyed now that they're broken up. What's the law here?
Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.
Drugmaker Teva is considering making a bid for Mylan, but has not yet made a decision on an offer, Dow Jones reported.
For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.
A company says it can help states protect Obamacare subsidies for residents by setting up an insurance exchange in just two months.
After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.
Get the best of CNBC in your inbox